



March Formulary Update

Effective March 31, 2022

New Formulary Medications:

- a. mesalazine (MEZAVANT) oral delayed and extended-release tablet

New Formulary Restricted Medications:

- a. acetaminophen parenteral injection restricted to:
 - post-op patients in whom other routes of acetaminophen (oral, feeding tube, or rectal) are contraindicated
 - neonates for patent ductus arteriosus (PDA) closure

Note: several implementation and medication safety requirements are needed prior to stocking this product. Sites will be notified once these have been completed.

- b. BC Cancer Additions: restricted to indications outlined in the BC Cancer Benefit Drug List and patients who are registered with BC Cancer
 - acalabrutinib (Calquence®) oral capsule
 - Bacillus Calmette-Guerin (Verity-BCG®) intravesicular

Updates to Formulary Restricted Medications:

- a. ferric derisomaltose (MONOFERRIC) injection restrictions changed to the following:
 - indications outlined by BC Renal AND patients who are registered with BC Renal *OR*
 - intolerance or poor response to oral iron supplements *OR* gastrointestinal malabsorption syndrome (e.g. inflammatory bowel disease) *AND*
 - hemoglobin less than 110 g/L and one of following:
 - ferritin less than 30 mcg/L *OR*
 - ferritin less than 200 mcg/L with iron saturation less than 20% *AND*
 - total dose required exceeds 300 mg IV iron elemental

Note: iron isomaltoside has been renamed by manufacturer to ferric derisomaltose.

Excluded Medications:

- a. brexpiprazole (REXULTI) oral tablet

March 31, 2022 For the information of physicians, nurses, and pharmacists. PLEASE POST	Formulary Changes	√	For further information contact: <i>Jessica Granberg</i> Medication Use Management Pharmacists mumpharmacist@northernhealth.ca
	Drug Discontinuation		
	Medication Change		